Arrowhead Pharmaceuticals Shareholders Witness 59% Decline Despite Recent 13% Surge

Arrowhead Pharmaceuticals (ARWR) has seen a 13% increase in its stock price in the past month, despite a 59% decline over the past three years. The company's revenue grew by 9.6% annually, indicating strong growth, yet the share price continued to fall. Analyst coverage suggests visibility into future growth, but the stock's performance diverges from its revenue, suggesting an opportunity for further investigation. Year-to-date, ARWR's stock is down 27% while the market is up 23%, potentially indicating unresolved challenges.